Odds for desensitization and remission fell as patients missed consecutive doses of peanut oral immunotherapy, according to a ...

Researchers conducting a clinical trial of immunotherapy drugs for people with head and neck squamous cell carcinomas (HNSCCs ...

Neoadjuvant chemoimmunotherapy is associated with significantly improved survival outcomes compared with standard ...

Nouscom has announced full safety and immunogenicity results from its phase 1b/2 trial of NOUS-209, an off-the-shelf ...

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept ...

The FDA recently approved an immunotherapy-based treatment option that can be administered by under the skin, injection. This ...

CERo’s technology works by grafting onto patients’ own T-cells a receptor that binds to a naturally occurring human antigen ...

A super-resolution microscopy technique offers an unparalleled glimpse into how monoclonal antibodies bind to their targets ...

OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that OST-HER2 is featured in ...

Adjuvant camrelizumab significantly improves event-free survival in patients with locoregionally advanced nasopharyngeal ...

A team of researchers from Cleveland Clinic Genomic Medicine share insights from an early set of 19,000 patients to receive ...

Head and neck squamous cell carcinomas responded better to a combination of two immunotherapies than to one immunotherapy ...